Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Peptide subunit |
Clinical data | |
Routes of administration | Intramuscular |
Identifiers | |
DrugBank |
Part of a series on the |
COVID-19 pandemic |
---|
![]() |
|
Medical response |
|
![]() |
UB-612 is a COVID-19 vaccine candidate developed by United Biomedical Asia [zh], and Vaxxinity, Inc.[1] It is a peptide vaccine.[2][3]
It is composed of SARS-CoV-2 S1-RBD protein and synthetic peptides representing T cell (Th and CTL) epitopes on the nucleocapsid, spike and membrane proteins. The multitope composition is differentiated from other solely spike-protein based vaccines. By recognition against epitopes on Spike (S1-RBD and S2) and non-Spike (N and M) structure proteins, UB-612 provides B-cell and T-cell memory immunity and offers a potential as a universal vaccine to fend off the Omicron variant and new emerging variants of concern.[4][5] Vaxxinity began seeking regulatory approval for UB-612 for use as a booster vaccine in the United Kingdom and Australia in 2022.[6][7]
Technology[edit]
UB-612 is a peptide vaccine incorporating multiple epitopes, including the spike protein receptor binding domain as well as other virus structural proteins.[1][3] The spike protein peptide is fused to an Fc domain of single-chain IgG1, and the other six peptides are derived from highly conserved sequences from the spike, nucleocapsid, and membrane proteins of SARS-CoV-1 and SARS-CoV-2. It also contains a proprietary UBITh1 peptide derived from the measles virus fusion protein, CpG oligonucleotides, and aluminum phosphate adjuvant to improve the immune response. It is produced in CHO cells.[2]
Clinical trials[edit]
In September 2020, phase I clinical trials of UB-612 started in Taiwan.[8] and in January 2021, phase II clinical trials began in Taiwan.[9] In February 2021, phase II/III clinical trials began.[10] Results from clinical trials showing positive safety and efficacy data were published in May 2022,[4] and in May-June 2023.[11][12]
In March 2022, Vaxxinity started an international phase III clinical trial of UB-612 as a heterologous booster vaccine against three approved platforms: mRNA, adenovirus vector, and inactivated virus.[13] The company announced positive topline data of the trial in December 2022[14] and positive results were published in January 2024.[15]
References[edit]
- ^ a b Liao G (27 June 2021). "Taiwan's second domestic COVID vaccine's midterm performance in phase II trials inferior to local competitor: experts". Taiwan News. Retrieved 8 July 2021.
- ^ a b Martínez-Flores D, Zepeda-Cervantes J, Cruz-Reséndiz A, Aguirre-Sampieri S, Sampieri A, Vaca L (12 July 2021). "SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants". Frontiers in Immunology. 12: 701501. doi:10.3389/fimmu.2021.701501. PMC 8311925. PMID 34322129.
- ^ a b "COVID-19 Vaccine". Vaxxinity. Archived from the original on 9 October 2021. Retrieved 9 October 2021.
- ^ a b Wang CY, Hwang KP, Kuo HK, Peng WJ, Shen YH, Kuo BS, et al. (May 2022). "A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants". The Journal of Clinical Investigation. 132 (10). doi:10.1172/JCI157707. PMC 9106357. PMID 35316221.
- ^ Guirakhoo F, Wang S, Wang CY, Kuo HK, Peng WJ, Liu H, et al. (October 2022). "High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster". The Journal of Infectious Diseases. 226 (8): 1401–1406. doi:10.1093/infdis/jiac241. PMC 9278180. PMID 35723969.
- ^ Lynch R (9 February 2023). "Vaxxinity moves HQ, jobs to Florida's Space Coast from Texas". Orlando Business Journal. American City Business Journals. Retrieved 26 February 2023.
- ^ Lorenz J (2 November 2022). "Phase 3 Trial of Vaxxinity's COVID-19 Vaccine as a Heterologous Booster Advances". ContagionLive. Retrieved 26 February 2023.
- ^ Clinical trial number NCT04545749 for "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine" at ClinicalTrials.gov
- ^ Clinical trial number NCT04683224 for "A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine" at ClinicalTrials.gov
- ^ Clinical trial number NCT04773067 for "A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers" at ClinicalTrials.gov
- ^ Wang CY, Peng WJ, Kuo BS, Ho YH, Wang MS, Yang YT, et al. (April 2023). Krammer F (ed.). "Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses". PLOS Pathogens. 19 (4): e1010870. doi:10.1371/journal.ppat.1010870. PMC 10153712. PMID 37079651.
- ^ Wang CY, Kuo BS, Lee YH, Ho YH, Pan YH, Yang YT, et al. (June 2023). "Targeting Multiple Conserved T-Cell Epitopes for Protection against COVID-19 Moderate-Severe Disease by a Pan-Sarbecovirus Vaccine". medRxiv.
- ^ Clinical trial number NCT05293665 for "Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine" at ClinicalTrials.gov
- ^ "Vaxxinity's Phase III Covid-19 booster trial meets endpoints". Clinical Trials Arena. 5 December 2022. Retrieved 25 February 2023.
- ^ Wang CY, Kuo BS, Lee YH, Ho YH, Pan YH, Yang YT, et al. (February 2024). "UB-612 pan-SARS-CoV-2 T cell immunity-promoting vaccine protects against COVID-19 moderate-severe disease". iScience. 27 (2): 108887. doi:10.1016/j.isci.2024.108887. PMC 10839960. PMID 38318376.
External links[edit]
![](https://upload.wikimedia.org/wikipedia/commons/thumb/3/32/Scholia_logo.svg/40px-Scholia_logo.svg.png)
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
Well, that’s interesting to know that Psilotum nudum are known as whisk ferns. Psilotum nudum is the commoner species of the two. While the P. flaccidum is a rare species and is found in the tropical islands. Both the species are usually epiphytic in habit and grow upon tree ferns. These species may also be terrestrial and grow in humus or in the crevices of the rocks.
View the detailed Guide of Psilotum nudum: Detailed Study Of Psilotum Nudum (Whisk Fern), Classification, Anatomy, Reproduction